The Stand Up To Cancer Translational Cancer Research Grants represent a new, focused effort to affect advances in cancer research as rapidly as possible through the creation of collaborative, international translational cancer research “Teams.” On August 2, 2012, SU2C announced the first team to receive a Translational Cancer Research Grant in collaboration with the Dutch Cancer Society (KWF Kankerbestrijiding). The grant is supported with money raised in connection with a November 2010 Dutch version of the Stand Up To Cancer televised fundraising event, Sta Op Tegen Kanker, which was broadcasted in the Netherlands under the auspices of the Dutch Cancer Society. The Sta Op Tegen Kanker International Translational Cancer Research Team includes researchers from the three largest cancer centers in the Netherlands: the Netherlands Cancer Institute, Erasmus MC and UMC Utrecht. €1.2 million will support the team over a four-year period.
For non-media related SU2C questions, please send an email to SU2C@aacr.org.
Sta Op Tegen Kanker International Translational Cancer Research Grant: Prospective Use of DNA-guided Personalized Cancer Treatment
Emile E. Voest, M.D., Ph.D., head of the Department of Medical Oncology at the University Medical Center (UMC) Utrecht in the Netherlands
René Bernards, Ph.D., head of the Division of Molecular Carcinogenesis at the Netherlands Cancer Institute
The goal of this project is to identify new ways in which DNA analysis can be used to guide the selection of the most appropriate personalized cancer treatments for patients. This research team will focus on “proof-of-principle” studies that include patients from three ongoing clinical studies: one on breast cancer and two on colorectal tumors. Read more.
Updated: August 2, 2012